Tech Company Financing Transactions
Forge Biologics Funding Round
Forge Biologics, based in Columbus, scored $40 million from Perceptive Advisors and Drive Capital.
Transaction Overview
Company Name
Announced On
7/23/2020
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Perceptive Advisors (Lead Investor) (Chris Garabedian)
Proceeds Purpose
Forge will use the proceeds of this financing to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021, and for the development of a novel gene therapy pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Columbus, OH 43004
USA
Columbus, OH 43004
USA
Phone
Undisclosed
Website
Email Address
Overview
Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Miller
Chief Medical Officer
Maria Escolar
Chief Operating Officer
Jaysson Eicholtz
Chief Technical Officer
David Dismuke
VP - Bus. Development
Erandi De Silva
VP - Bus. Development
Magdalena Tyrpien
VP - Finance
Steve Goden
VP - Finance
Christina Perry
VP - Marketing
Hannah Munizza
VP - Regulatory Affairs
Meghan Leonard
VP - Regulatory Affairs
Chris Shilling
VP - Sales
Laura Carfagna
Browse more venture capital transactions:
Prev: 7/23/2020: Mobalytics venture capital transaction
Next: 7/23/2020: Dexterity venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs